Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005660
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2000-05-12
Brief Title:
The Evaluation of Oral Acitretin in the Treatment of Psoriasis Cutaneous Disorders of Keratinization Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
The Evaluation of Oral Acitretin in the Treatment of Psoriasis Cutaneous Disorders of Keratinization Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases
Status:
COMPLETED
Status Verified Date:
2001-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a continuing study which evaluates the long-term safety and efficacy of oral acitretin in an open manner in the treatment of psoriasis cutaneous disorders of keratinization multiple basal cell carcinomas and other retinoid responsive diseases
Detailed Description:
This is a continuing study which evaluates the long-term safety and efficacy of oral acitretin in an open manner in the treatment of psoriasis cutaneous disorders of keratinization multiple basal cell carcinomas and other retinoid responsive diseases
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 77-C-0172 | None | None | None |